[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

ProGrow Pharma Partners: Market Research Reports

ProGrow Pharma (PGP) Partners is a professional team of all kinds of specialists that offers exclusive advisory services to healthcare business. Over a decade it has been researching healthcare and biotechnological sectors at the global market to provide key players with in-depth data and feasible solutions. In addition, ProGrow Pharma studies the investment environment within the sector to ensure effective cooperation between the investors and firms that solicit for financing support. PGP has years-long partnership relations with firms engaged in the pharma industry:

  • Market leaders
  • CROs
  • Innovators
  • Venture Capitalists
  • Private Equity investors

The company employs viable estimating methods and other effective methodology to assist clients in maximizing their business potential. PGP experts have in-depth knowledge of the scientific innovations, the production of drugs, medical trials, and the status of therapeutical, molecular and other specific medical development.

Apart from research and development in the healthcare sector PGP monitors its competitive landscape, supply, and demand, product launch and other technical and financial activities of the key participants.

The research we provide covers all geographies and focuses on such knowledge as:

  • Mergers and Acquisitions
  • Due Diligence
  • Financial Risks and Opportunities
  • Growth Drivers
  • Start-ups Evaluation
  • Brad Development
  • Strategic Partnership
  • Regulatory Policies in the sector
  • Product Launch
  • Operational Potential
  • Fund Raising Options

The reports you can order form us will contain the information which is feature-oriented for your company. Our offerings are reasonably priced and delivered on time helping you to identify challenges and evaluate opportunities on the market.

Publications found: 7
Sort by:

Parkinson's Disease: Molecular Landscape & Future Disease Modifying Targeted Therapies

US$ 3,200.00

... making we are publishing our latest in the series“ Parkinson's Disease -Molecular Landscape & Future Disease Modifying Targeted Therapies” The success of targeted therapies in ... PD but few which are comprehensive both in defining the molecular landscape in PD, unmet need, promising drugs in the pipeline their ...

September 2018 34 pages

Exploring Opportunities in Niche Therapies – Human Cytomegalovirus (HCMV) Infections

US$ 2,500.00

... for these patients. In this report we discuss the recently approved therapies for CMV infections, other drugs and vaccines in the pipeline ...

April 2018 42 pages

Calcitonin – Gene Related Peptide (CGRP) Antagonists /Monoclonal Antibodies: New Targeted Therapies for Migraine

US$ 2,500.00

... and physiology of the disease. Novel mechanisms, such as, 5-hydroxytriptamine (5-HT) receptors, Calcitonin-Gene Related Peptide (CGRP), pituitary adenylate cyclase-activating polypeptide (PACAP), Glutamate etc ...

February 2018 33 pages

Innovation in India Series: An Analysis of Select Pharma Biotech Start-ups

US$ 2,500.00

... west IPO is not the popular route of raising capital in India for innovator companies as the public perception, appreciation and understanding of the ... worldwide. We elaborate on this urgent need and the potential of an innovative antibiotic for serious infections. ii) Vitas Pharma also focuses on developing ...

February 2018 40 pages

Therapeutic Class Report: Oral Mucositis

US$ 3,000.00

... , there are very few targeted drugs or therapeutic options available to the patient. Untreated it can ... a grave need for systematic management of oral mucositis triggered by anti-neoplastic protocols. Several products ... literature, industry publications, company reports and published information, and statistical ...

September 2017 41 pages

Oral Mucositis - An Analysis of Drugs in Development, Market Opportunity, unmet need, Disease prevalence and occurrence in cancer in Various Geographies

US$ 3,000.00

... of life. There is a grave need for systematic management of oral mucositis triggered by anti-neoplastic protocols. Several products are marketed as palliative ... . Only drug Amgen/SOBI’s Kepivance (palifermin) is approved for oral mucositis in transplantation; but is contra-indicated for solid tumor patients. ...

September 2017 41 pages

Poly(adenosine diphosphate [ADP]–ribose) Polymerases (PARPs) Inhibitors Successful targeting of DNA Repair Pathways by PARP Inhibitors – Current and Future Potential

US$ 3,200.00

Poly(adenosine diphosphate [ADP]–ribose) polymerases (PARPs) activity is essential for the ... class of drugs in other solid tumors. PARP inhibitors have demonstrated clear patient benefit in germline ... this report, we highlight the rationale of inhibiting PARP in different cancers and the promising clinical data ...

July 2017 56 pages